IRWD
Ironwood Pharmaceuticals, Inc.
$4.22
+1.20%
2026-05-08
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Key Fundamentals
P/E Ratio
6.71
Forward P/E
2.88
EPS (TTM)
$0.62
Revenue Growth (YoY)
158.9%
Profit Margin
28.3%
Market Cap
$684.8M
Avg Volume (10D)
2.6M
Recent Breakout Signals
No recent breakout signals detected for IRWD.
Recent Price Range (60 Days)
60D High
$4.88
60D Low
$2.95
Avg Volume
2.7M
Latest Close
$4.22
Get breakout alerts for IRWD
Sign up for Breakout Scanner to receive daily notifications when IRWD triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Ironwood Pharmaceuticals, Inc. (IRWD) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors IRWD daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. IRWD operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.